W. Keith

发表

Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3.

Walter Kolch, Katrina Stevenson, W. Kolch, 2006, Cancer research.

Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors.

A. Schätzlein, A. Bilsland, W. Keith, 2005, Cancer research.

Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition

Meenakshi Malhotra, Alan Bilsland, Amr Amin, 2015, Seminars in cancer biology.

Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell.

Nedime Serakinci, Moustapha Kassem, Stuart P. Atkinson, 2006, Regenerative medicine.

Identification of a Selective G1-Phase Benzimidazolone Inhibitor by a Senescence-Targeted Virtual Screen Using Artificial Neural Networks12

Masashi Narita, Angelo Pugliese, Alan E. Bilsland, 2015, Neoplasia.

Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition

M. Narita, C. Torrance, D. Bennett, 2015, Molecular biology of the cell.

A systems biology approach to Down syndrome: identification of Notch/Wnt dysregulation in a model of stem cells aging.

C. Svendsen, W. Keith, I. Bellantuono, 2009, Biochimica et biophysica acta.

Progeroid syndromes: models for stem cell aging?

G. Sanguinetti, W. Keith, I. Bellantuono, 2011, Biogerontology.

A Small Molecule Modulator of Prion Protein Increases Human Mesenchymal Stem Cell Lifespan, Ex Vivo Expansion, and Engraftment to Bone Marrow in NOD/SCID Mice

W. Keith, I. Bellantuono, A. Thrasher, 2012, Stem cells.

Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization.

W. Keith, N. Morrison, S. Hoare, 2000, Neoplasia.

A ‘synthetic-sickness’ screen for senescence re-engagement targets in mutant cancer backgrounds

Ceri M. Wiggins, M. Narita, C. Torrance, 2017, PLoS genetics.

Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Gloria S. Huang, A. Azmi, Shijun Mi, 2015, Seminars in cancer biology.

A mutation in a functional Sp 1 binding site of the telomerase RNA gene ( hTERC ) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria

T. Vulliamy, Jiangqin Zhao, A. Bilsland, 2015 .

A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria

T. Vulliamy, Jiangqin Zhao, A. Bilsland, 2004, BMC blood disorders.

Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954

R. Glasspool, Jiangqin Zhao, A. Bilsland, 2001, Oncogene.

Mining Cellular Senescence for Drug Targets

A. Bilsland, W. Keith, 2010 .

Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells

E. Parkinson, C. Paraskeva, V. Brunton, 1999, Oncogene.

From stem cells to cancer: balancing immortality and neoplasia

W. Keith, 2004, Oncogene.

Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer

E. K. Parkinson, E. Parkinson, W. Keith, 1997, Oncogene.

A Novel Pyrazolopyrimidine Ligand of Human PGK1 and Stress Sensor DJ1 Modulates the Shelterin Complex and Telomere Length Regulation

A. Turnbull, A. Bilsland, Katrina Stevenson, 2019, Neoplasia.

Ectopically hTERT expressing adult human mesenchymal stem cells are less radiosensitive than their telomerase negative counterpart.

R. Christensen, J. Alsner, G. Saretzki, 2007, Experimental cell research.

A role for NANOG in G1 to S transition in human embryonic stem cells through direct binding of CDK6 and CDC25A

M. Stojkovic, M. Lako, T. Strachan, 2009, The Journal of cell biology.

A role for NANOG in G 1 to S transition in human embryonic stem cells through direct binding of CDK 6 and CDC 25 A

M. Stojkovic, M. Lako, T. Strachan, 2009 .

Dysregulated expression of the major telomerase components in leukaemic stem cells

T. Holyoake, W. Keith, M. Drummond, 2005, Leukemia.

Drug Insight: cancer cell immortality—telomerase as a target for novel cancer gene therapies

A. Bilsland, W. Keith, T. Evans, 2004, Nature Clinical Practice Oncology.

Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization

S. Kaye, W. Keith, J. Going, 1998, Oncogene.

Cancer stem cells: opportunities for novel diagnostics and drug discovery.

W. Keith, 2006, European journal of cancer.

MicroRNA and senescence: the senectome, integration and distributed control.

A. Bilsland, W. Keith, J. Revie, 2013, Critical reviews in oncogenesis.

Tissue invasion and metastasis: Molecular, biological and clinical perspectives.

A. Azmi, M. Ciriolo, A. Georgakilas, 2015, Seminars in cancer biology.

Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Mark A Feitelson, Alan Bilsland, Amr Amin, 2015, Seminars in cancer biology.

Broad targeting of angiogenesis for cancer prevention and therapy

A. Azmi, W. Rathmell, D. Ribatti, 2015, Seminars in cancer biology.

Cancer prevention and therapy through the modulation of the tumor microenvironment.

A. Azmi, D. Felsher, R. Whelan, 2015, Seminars in cancer biology.

Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

A. Azmi, G. Pawelec, E. Ryan, 2015, Seminars in cancer biology.

Isolation, Culture, and Transfection of Melanocytes

D. Bennett, E. Sviderskaya, P. Goff, 2014, Current protocols in cell biology.

Broad targeting of resistance to apoptosis in cancer

Carmela Fimognari, Alan Bilsland, Amr Amin, 2015, Seminars in cancer biology.

Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression

C. Milagre, R. Marais, D. Bennett, 2011, Pigment cell & melanoma research.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Gloria S. Huang, Rob J. Kulathinal, C. Smythe, 2015, Seminars in cancer biology.

A multi-targeted approach to suppress tumor-promoting inflammation.

A. Azmi, L. Ricciardiello, A. Bishayee, 2015, Seminars in cancer biology.

Therapeutic targeting of replicative immortality

A. Azmi, P. Yaswen, G. Firestone, 2015, Seminars in cancer biology.

Dynamic Telomerase Gene Suppression via Network Effects of GSK3 Inhibition

Alan E. Bilsland, Katrina Stevenson, Jon Roffey, 2009, PloS one.

Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance.

M. Daidone, A. Gronchi, N. Zaffaroni, 2012, Neuro-oncology.

High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma

N. Zaffaroni, W. Keith, S. Hoare, 2008, British Journal of Cancer.

The genetic basis of human keratinocyte immortalisation in squamous cell carcinoma development: the role of telomerase reactivation.

E. K. Parkinson, W. Keith, R. Newbold, 1997, European journal of cancer.

Response to ‘Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanisms’

N. Zaffaroni, A. Bilsland, W. Keith, 2012, Oncogene.

A gene expression signature classifying telomerase and ALT immortalisation reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT

Nedime Serakinci, Alan Bilsland, Claire J. Cairney, 2009, Oncogene.

Epigenetic control of cellular senescence in disease: opportunities for therapeutic intervention

Stuart P. Atkinson, W. Keith, Stuart P. Atkinson, 2007, Expert Reviews in Molecular Medicine.

Targeting Telomerase: Therapeutic Options for Cancer Treatment

Alan Bilsland, A. Bilsland, W. Keith, 2008 .

Stem cell ageing: does it happen and can we intervene?

W. Keith, I. Bellantuono, W. Nicol Keith, 2007, Expert Reviews in Molecular Medicine.

The hTERT and hTERC telomerase gene promoters are activated by the second exon of the adenoviral protein, E1A, identifying the transcriptional corepressor CtBP as a potential repressor of both genes.

R. Glasspool, W. Keith, S. Hoare, 2005, Neoplasia.

Telomerase-directed molecular therapeutics

R. Glasspool, A. Bilsland, W. Keith, 2002, Expert Reviews in Molecular Medicine.

Mathematical Model of a Telomerase Transcriptional Regulatory Network Developed by Cell-Based Screening: Analysis of Inhibitor Effects and Telomerase Expression Mechanisms

Yu Liu, Alan E. Bilsland, Katrina Stevenson, 2014, PLoS Comput. Biol..

Cancer cell senescence: a new frontier in drug development.

M. Narita, C. Torrance, D. Bennett, 2012, Drug discovery today.

Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms.

N. Jamieson, W. Keith, K. Oien, 2009, Biochimica et biophysica acta.

Silencing of the expression of pluripotent driven-reporter genes stably transfected into human pluripotent cells.

M. Stojkovic, M. Lako, T. Strachan, 2008, Regenerative medicine.

Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.

A. Bilsland, W. Keith, Alan E Bilsland, 2005, Neoplasia.

Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase

I. Ganly, A. Bilsland, W. Keith, 2003, Oncogene.

Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3.

R. Glasspool, A. Bilsland, W. Keith, 2000, Neoplasia.

Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity.

W. Keith, C. Cairney, 2008, Biochimie.

Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters.

R. Glasspool, Stuart P. Atkinson, W. Keith, 2005, Cancer research.

Involvement of NF‐Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene

Jiangqin Zhao, A. Bilsland, W. Keith, 2003, FEBS letters.

Cloning and characterization of human and mouse telomerase RNA gene promoter sequences

E. Parkinson, R. McFarlane, W. Keith, 1998, Oncogene.

Downregulation of Multiple Stress Defense Mechanisms During Differentiation of Human Embryonic Stem Cells

M. Stojkovic, M. Lako, G. Saretzki, 2008, Stem cells.

Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms

M Ashcroft, M. Ashcroft, A. Bilsland, 2006, Oncogene.

Cellular immortality and cancer: From telomerase to cancer stem cells

J. Shay, W. Keith, 2009 .

Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma

Alan Bilsland, Jon Roffey, N. Jamieson, 2010, BMC Genomics.

TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression.

Alan Bilsland, N. Zaffaroni, A. Bilsland, 2010, Neoplasia.

Therapeutic potential of adult stem cells.

W. Keith, N. Serakinci, 2006, European journal of cancer.

The PTEN regulator DJ‐1 is associated with hTERT expression in clear cell renal cell carcinoma

B. Hallberg, W. Keith, G. Roos, 2009, International journal of cancer.

Telomerase upregulation is a postcrisis event during senescence bypass and immortalization of two Nijmegen breakage syndrome T cell cultures

W. Keith, G. Roos, J. K. Siwicki, 2010, Aging cell.

Progeroid syndromes: models for stem cell aging?

W. Keith, I. Bellantuono, G. Sanguinetti, 2012, Biogerontology.

MDM2 negatively regulates the human telomerase RNA gene promoter

Jiangqin Zhao, Alan Bilsland, Jiangqin Zhao, 2005, BMC Cancer.

Amplification of the topoisomerase ii α gene in a non‐small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase ii α and β loci in normal tissue

S. Beecham, Robert Brown, W. Keith, 1992 .